Director of NHLBI receives American Heart Association Research Achievement Award for “dynamic leadership” of heart studies, especially among minorities
American Heart Association Meeting Report
Embargoed until 5 a.m. CT / 6 a.m. ET on Monday, November 12, 2018
CHICAGO, Nov. 10 – The American Heart Association (AHA) today presented its 2018 Research Achievement Award to Gary Gibbons, M.D., director of the National Heart, Lung and Blood Institute, “for his dynamic leadership of studies of cardiovascular health and disease, especially in minority populations.”
Gibbons received the award on Sunday, November 11, during opening ceremonies at the American Heart Association’s Scientific Sessions 2018, a premier global exchange of the latest advances in cardiovascular science for researchers and clinicians at McCormick Place convention center in Chicago. AHA President Ivor Benjamin, M.D., of the Medical College of Wisconsin in Milwaukee, made the presentation.
In presenting the award, Benjamin noted that as leader of the National Heart, Lung, and Blood Institute (NHLBI), Gibbons oversees the third largest National Institutes of Health component, with a staff of 917 federal employees and an annual budget of more than $3 billion. “He has launched bold, new initiatives to advance curative therapies for rare diseases and to promote precision medicine and science for the 21st Century,” AHA’s president said.
Gibbons is leading multi-disciplinary research studying racial and ethnic disparities in cardiovascular health. The investigators recently began recruiting 3,200 individuals, Benjamin said, “to study whether race-ancestry differences in cardiovascular disease reflect the influence of a unique interplay between genomic variation, social determinants and environmental factors that influence the origins of blood vessel disease.”
Under Gibbons’ guidance, researchers are developing a dense set of ancestry-informative markers that reaches beyond currently available data, Benjamin said.
Earlier research by Gibbons and his team “contributed importantly” to identifying factors implicated in the development of vascular diseases, the AHA award citation said. “As a young investigator, he was at the leading edge of the burgeoning field of vascular biology and was a key intellectual driver of the emerging conceptual framework of vascular remodeling and clarified cellular process and molecular mediators that govern vascular structure in health and disease. His team created new insights into ways to mediate vascular remodeling and validated targets for a new generation of therapies designed to treat vascular disease.”
Critical insights from Gibbons’ findings led to clinical trials proving the beneficial effects of angiotensin receptor blockade on aneurysm formation in patients with Marfan Syndrome, AHA’s award citation said.
Before becoming NHLBI director in 2012, Gibbons served on medical faculties at Stanford University, Harvard Medical School and Morehouse School of Medicine. He also is a senior investigator for the National Human Genome Research Institute.
- Available video/audio interviews, B-roll, animation and images may be downloaded from the right column of the release link: https://newsroom.heart.org/news/director-of-nhlbi-receives-american-heart-association-research-achievement-award-for-dynamic-leadership-of-heart-studies-especially-among-minorities?preview=bac919bda290fa750044cfbd1da7eab5
- For more news at AHA Scientific Sessions 2018, follow us on Twitter @HeartNews #AHA18.
Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at https://www.heart.org/en/about-us/aha-financial-information.
About the American Heart Association
The American Heart Association is a leading force for a world of longer, healthier lives. With nearly a century of lifesaving work, the Dallas-based association is dedicated to ensuring equitable health for all. We are a trustworthy source empowering people to improve their heart health, brain health and well-being. We collaborate with numerous organizations and millions of volunteers to fund innovative research, advocate for stronger public health policies, and share lifesaving resources and information. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1.
For Media Inquiries: 214-706-1173
Carrie Thacker: 214-706-1665; firstname.lastname@example.org
Nov. 10-12, 2018:
AHA News Media Office at the McCormick Place Convention Center: 312-791-6820.
For Public Inquiries: 1-800-AHA-USA1 (242-8721)